Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

Rectal or Anal Cancer Clinical Trial

Official title:

A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02199236
• Other study ID #: 14-104
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: July 2014
• Est. completion date: July 2024

Study information

• Verified date: July 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to see what amount of radiation is safe to give to rectal or anal cancer patients who are being treated with a procedure called brachytherapy.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 15
• Est. completion date: July 2024
• Est. primary completion date: July 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed locally residual or recurrent cancer of the rectum or anus

• Prior pelvic EBRT

• Age > or = to 18 years

• ECOG performance status 0, 1, or 2

• At least 4 weeks from prior major surgery or radiotherapy

• Have undergone Surgical, Medical and Radiation Oncology evaluations to confirm :

• Eligible for infusional 5-FU or capecitabine

• Will not undergo surgery for the study disease

• Able to receive HDR brachytherapy ANC = 1.5 cells/mm3 and PLT =100,000/mm3

• Adequate Renal function: Creatinine <1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of = 50cc/min

• Adequate Hepatic functions: Bilirubin less than 1.5 mg/dL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)

• AST or ALT <3xULN, or <5x ULN if known liver metastases

• Normal Cardiac function:

• No active coronary artery disease;

• No New York Heart Association class II, III or IV disease;

• No arrhythmia requiring treatment

• Maximum tumor length of 7 cm at time of brachytherapy treatment start

Exclusion Criteria:

• Women who are pregnant.

• Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire treatment period and after receipt of brachytherapy. Male subjects must also agree to use effective contraception during the treatment period and until 1 year after the completion of brachytherapy.

• Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study.

• Patients on concurrent anti-cancer therapy other than that allowed in the study.

• Contraindications to general anesthesia

Related Conditions & MeSH terms

• Anus Neoplasms
• Rectal or Anal Cancer

Intervention

Radiation:
• endorectal brachytherapy
Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).

Drug:
• concurrent capecitabine or 5-FU
Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only. Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days.

Behavioral:
• Questionnaires
Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Basking Ridge (Follow Up Only)	Basking Ridge	New Jersey
United States	Memorial Sloan Kettering Commack (Consent and Follow up)	Commack	New York
United States	Memorial Sloan Kettering Westchester (Follow Up Only)	Harrison	New York
United States	Memorial Sloan Kettering Monmouth (Follow Up Only)	Middletown	New Jersey
United States	Memorial Sloan Kettering Cancer Center	New York	New York
United States	Memorial Sloan Kettering Rockville Center (Follow Up Only)	Rockville Centre	New York
United States	Memorial Sloan Kettering Nassau (Follow-Up only)	Uniondale	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	maximum tolerated dose (MTD)	will employ a standard 3+3 dose-escalation scheme. Patients will be accrued to the study in cohorts of 3. An initial cohort of 3 patients will be treated to each dose. The dose level will be escalated if none of the 3 patients exhibits any DLT within 90 days of completion of brachytherapy. Dose escalation will not take place until every patient in the prior dose cohort has been monitored for 90 days.	1 year
Secondary	tumor response	MRI with DCE & DWI (unless contraindicated) after brachytherapy	3, 6, and 12 months

External Links

•   Memorial Sloan Kettering Cancer Center